Pluristem Therapeutics Inc. (NASDAQ:PSTI) – Equities researchers at Seaport Global Securities lifted their FY2018 earnings per share estimates for shares of Pluristem Therapeutics in a note issued to investors on Monday, May 21st, Zacks Investment Research reports. Seaport Global Securities analyst V. Bernardino now anticipates that the biotechnology company will earn ($0.25) per share for the year, up from their prior forecast of ($0.34).
PSTI has been the subject of several other research reports. Maxim Group set a $3.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Zacks Investment Research cut shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 1st. ValuEngine upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Finally, MED reiterated a “positive” rating on shares of Pluristem Therapeutics in a research note on Monday, April 23rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Pluristem Therapeutics currently has an average rating of “Buy” and a consensus target price of $3.38.
Pluristem Therapeutics traded down $0.07, hitting $1.26, during midday trading on Wednesday, Marketbeat.com reports. The company’s stock had a trading volume of 1,380,700 shares, compared to its average volume of 444,307. Pluristem Therapeutics has a 1-year low of $1.06 and a 1-year high of $2.12. The stock has a market capitalization of $155.21 million, a price-to-earnings ratio of -3.94 and a beta of 0.28.
Pluristem Therapeutics (NASDAQ:PSTI) last posted its earnings results on Thursday, May 10th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08.
An institutional investor recently bought a new position in Pluristem Therapeutics stock. Meitav Dash Investments Ltd. bought a new stake in Pluristem Therapeutics Inc. (NASDAQ:PSTI) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 100,000 shares of the biotechnology company’s stock, valued at approximately $138,000. Meitav Dash Investments Ltd. owned 0.09% of Pluristem Therapeutics as of its most recent SEC filing. 3.97% of the stock is owned by institutional investors.
In other Pluristem Therapeutics news, Director Mark Germain sold 45,873 shares of the firm’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $1.48, for a total value of $67,892.04. Following the transaction, the director now directly owns 525,584 shares of the company’s stock, valued at approximately $777,864.32. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.20% of the stock is owned by company insiders.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.